Superworth

Absci revenue ABSI

Sales by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
$1.6M
Latest quarter, Q2 FY26
$318K
−46% on a year earlier
Fiscal year 2025
$2.8M
−38% on the year before

Absci's revenue was $1.6M over the twelve months to Jun 30, 2026, down 62% on a year earlier.

In its latest quarter, Q2 FY26, it was $318K, down 46% on the same quarter a year before.

Over the five fiscal years to FY2025 it shrank 10% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$2.8M−38%
FY2024$4.5M−21%
FY2023$5.7M−1%
FY2022$5.7M+20%
FY2021$4.8M+0%
FY2020$4.8Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$318K−46%$1.6M
Q1 FY26$215K−82%$1.8M
Q4 FY25$650K−2%$2.8M
Q3 FY25$378K−78%$2.8M
Q2 FY25$593K−53%$4.1M
Q1 FY25$1.2M+31%$4.8M
Q4 FY24$665K+97%$4.5M
Q3 FY24$1.7M+129%$4.2M
Q2 FY24$1.3M−62%$3.3M
Q1 FY24$898K−29%$5.3M
Q4 FY23$338K−78%$5.7M
Q3 FY23$744K−69%$6.9M

Against its peers

Companies in Medical - Diagnostics & Research nearest Absci's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
ABSIAbsci$1.6M−62% a year
CDNACareDx$458.1M+34% a year
VCYTVeracyte$561.9M+17% a year
BLLNBillionToOne$397.4M+90% a year
NRCNRC Health$140M−0% a year
LNTHLantheus$1.6B+2% a year
CAICaris Life Sciences$989.6M+85% a year
BIOBio-Rad Laboratories$2.6B+1% a year
Peer median$561.9M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Absci

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.